These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: A case report. Wako S; Ikeguchi R; Toda K; Kobayashi M; Miyata R; Kuramochi H; Ichihara A; Shimizu Y; Kitagawa K J Neuroimmunol; 2023 Jan; 374():578010. PubMed ID: 36508929 [TBL] [Abstract][Full Text] [Related]
48. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma. Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905 [TBL] [Abstract][Full Text] [Related]
49. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941 [TBL] [Abstract][Full Text] [Related]
50. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424 [TBL] [Abstract][Full Text] [Related]
51. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807 [TBL] [Abstract][Full Text] [Related]
52. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report. Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109 [TBL] [Abstract][Full Text] [Related]
53. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. Gao CA; Weber UM; Peixoto AJ; Weiss SA J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673 [TBL] [Abstract][Full Text] [Related]
54. Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma. Kato T; Nagahara A; Kawamura N; Nakata W; Soda T; Matsuzaki K; Hatano K; Kawashima A; Ujike T; Imamura R; Nishimura K; Takada S; Tsujihata M; Yamaguchi S; Takao T; Nakai Y; Nakayama M; Nonomura N; Uemura M Anticancer Res; 2021 Nov; 41(11):5811-5816. PubMed ID: 34732455 [TBL] [Abstract][Full Text] [Related]
55. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent. Thibault C; Vano Y; Soulat G; Mirabel M Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497 [No Abstract] [Full Text] [Related]
56. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553 [TBL] [Abstract][Full Text] [Related]
57. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? Özyurt E; Özçelik S; Sürmeli H; Çelik M; Ayhan M; Özçelik M J Oncol Pharm Pract; 2022 Mar; 28(2):462-465. PubMed ID: 34558355 [TBL] [Abstract][Full Text] [Related]
58. Pituitary adenoma apoplexy with initial presentation mimicking bacterial meningoencephalitis: a case report. Huang WY; Chien YY; Wu CL; Weng WC; Peng TI; Chen HC Am J Emerg Med; 2009 May; 27(4):517.e1-4. PubMed ID: 19555639 [TBL] [Abstract][Full Text] [Related]
59. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699 [TBL] [Abstract][Full Text] [Related]
60. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Yekedüz E; Ertürk İ; Tural D; Karadurmuş N; Karakaya S; Hızal M; Arıkan R; Arslan Ç; Taban H; Küçükarda A; Öztaş NŞ; Sever ÖN; Uçar G; Can O; Şendur MA; Demirci U; Kılıçkap S; Çiçin İ; Öksüzoğlu B; Özgüroğlu M; Ürün Y Future Oncol; 2021 Dec; 17(35):4861-4869. PubMed ID: 34726480 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]